MX2015013092A - Modificación y nuevas composiciones de proteínas secretoglobinas de humano. - Google Patents
Modificación y nuevas composiciones de proteínas secretoglobinas de humano.Info
- Publication number
- MX2015013092A MX2015013092A MX2015013092A MX2015013092A MX2015013092A MX 2015013092 A MX2015013092 A MX 2015013092A MX 2015013092 A MX2015013092 A MX 2015013092A MX 2015013092 A MX2015013092 A MX 2015013092A MX 2015013092 A MX2015013092 A MX 2015013092A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- isoforms
- preparations
- novel
- novel compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000011274 Secretoglobin Human genes 0.000 title 1
- 108050001520 Secretoglobin Proteins 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 4
- 108010029485 Protein Isoforms Proteins 0.000 abstract 4
- 238000002360 preparation method Methods 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 108090000203 Uteroglobin Proteins 0.000 abstract 2
- 102100031083 Uteroglobin Human genes 0.000 abstract 2
- 101000777301 Homo sapiens Uteroglobin Proteins 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000055576 human SCGB1A1 Human genes 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000007845 reactive nitrogen species Substances 0.000 abstract 1
- 239000003642 reactive oxygen metabolite Substances 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyrrole Compounds (AREA)
Abstract
Han sido generadas nuevas composiciones de la proteína CC10 de humano recombinante al modificar in vitro la proteína pura químicamente. Se han generado diversas preparaciones sintéticas nuevas que contienen isoformas de rhCC10 modificada químicamente a través de los procesos que utilizan especies de oxigeno reactivo y especies de nitrógeno reactivo. Estas preparaciones contienen nuevas isoformas de rhCC10, la que ha sido caracterizada con propiedades biológicas alteradas o mejoradas comparada con la proteína sin modificar. Las preparaciones que contienen nuevas isoformas, pueden ser utilizadas como estándares para identificar y caracterizar las isoformas de la proteína CC10 nativa que se presentan de manera natural a partir de sangre u orina, y finalmente, medir nuevos biomarcadores basados en CC10 para evaluar el estatus de enfermedad del paciente. También, estas preparaciones pueden ser utilizadas para tratar condiciones respiratorias, autoinmunes, inflamatorias y otras condiciones médicas que no son tratadas efectivamente con la proteína sin modificar.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/843,773 US9394349B2 (en) | 2013-03-15 | 2013-03-15 | Modification and compositions of human secretoglobin proteins |
| PCT/US2014/030117 WO2014145368A2 (en) | 2013-03-15 | 2014-03-17 | Modification and novel compositions of human secretoglobin proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015013092A true MX2015013092A (es) | 2016-06-02 |
Family
ID=51530119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013092A MX2015013092A (es) | 2013-03-15 | 2014-03-17 | Modificación y nuevas composiciones de proteínas secretoglobinas de humano. |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9394349B2 (es) |
| EP (2) | EP3403666A1 (es) |
| JP (2) | JP6670987B2 (es) |
| KR (1) | KR20160030076A (es) |
| CN (1) | CN105744946A (es) |
| AU (1) | AU2014233127A1 (es) |
| BR (1) | BR112015021266A2 (es) |
| CA (1) | CA2907439A1 (es) |
| IL (1) | IL241417A0 (es) |
| MX (1) | MX2015013092A (es) |
| RU (1) | RU2015144360A (es) |
| SG (1) | SG11201507277YA (es) |
| WO (1) | WO2014145368A2 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9394349B2 (en) * | 2013-03-15 | 2016-07-19 | Therabron Therapeutics, Inc. | Modification and compositions of human secretoglobin proteins |
| US12162914B2 (en) | 2013-03-15 | 2024-12-10 | Apc Research Assets Llc | Modification and compositions of human secretoglobin proteins |
| WO2016106198A1 (en) * | 2014-12-22 | 2016-06-30 | The Regents Of The University Of California | Compositions and methods for generating antigens, antibodies, and immunotherapeutic compositions and methods |
| JP6827113B2 (ja) | 2017-01-21 | 2021-02-10 | 広州白雲山漢方現代薬業有限公司Ｇｕａｎｇｚｈｏｕ Ｈａｎｆａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． | シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用 |
| WO2020113232A1 (en) * | 2018-11-30 | 2020-06-04 | Apc Research Assets Llc | Compositions and methods of use for secretoglobins to protect the glycocalyx via interactions with heparan sulfate proteoglycan proteins |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1006919A3 (nl) * | 1993-03-15 | 1995-01-24 | Ley Marc Jozef Philemon De | Farmaceutisch preparaat op basis van clara celeiwit cc10, en het gebruik daarvan als geneesmiddel en diagnosticum. |
| US20040047857A1 (en) * | 1997-05-28 | 2004-03-11 | Pilon Aprile L. | Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production |
| US20060281681A1 (en) * | 1997-05-28 | 2006-12-14 | Pilon Aprile L | Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease |
| US20030008816A1 (en) | 1997-05-28 | 2003-01-09 | Pilon Aprile L. | Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production |
| AU5551299A (en) | 1998-08-13 | 2000-03-06 | Trustees Of The University Of Pennsylvania, The | Method of identifying proteins |
| US6953666B1 (en) | 1998-11-06 | 2005-10-11 | Emory University | Biomarkers for oxidative stress |
| WO2004101824A1 (ja) | 2003-05-14 | 2004-11-25 | Shionogi & Co., Ltd. | 慢性閉塞性肺疾患の検出方法 |
| EP1654379A4 (en) | 2003-06-26 | 2007-01-17 | Lifesensors Inc | METHOD AND COMPOSITIONS FOR IMPROVED PROTEIN EXPRESSION AND CLEANING |
| CN1580261A (zh) * | 2003-08-06 | 2005-02-16 | 上海富纯中南生物技术有限公司 | Cc10蛋白的制备及应用 |
| CN1886152A (zh) | 2003-11-14 | 2006-12-27 | 阿尔萨公司 | 在药物辐射赋形剂制剂中药物氧化的最小化 |
| US20060275794A1 (en) | 2005-03-07 | 2006-12-07 | Invitrogen Corporation | Collections of matched biological reagents and methods for identifying matched reagents |
| US8133859B2 (en) | 2006-09-27 | 2012-03-13 | The United States Of America As Represented By The Department Of Health And Human Services | SCGB3A2 as a growth factor and anti-apoptotic agent |
| US20090004684A1 (en) | 2007-05-23 | 2009-01-01 | Claudia Susanne Maier | Compositions and Methods for Detection and Quantification of Protein Oxidation |
| MX2012004409A (es) * | 2009-10-15 | 2012-08-23 | Clarassance Inc | Proteina recombinante de humano cc10 para el tratamiento de la influenza. |
| US9394349B2 (en) * | 2013-03-15 | 2016-07-19 | Therabron Therapeutics, Inc. | Modification and compositions of human secretoglobin proteins |
-
2013
- 2013-03-15 US US13/843,773 patent/US9394349B2/en active Active
-
2014
- 2014-03-17 CA CA2907439A patent/CA2907439A1/en not_active Abandoned
- 2014-03-17 KR KR1020157029582A patent/KR20160030076A/ko not_active Ceased
- 2014-03-17 AU AU2014233127A patent/AU2014233127A1/en not_active Abandoned
- 2014-03-17 WO PCT/US2014/030117 patent/WO2014145368A2/en active Application Filing
- 2014-03-17 SG SG11201507277YA patent/SG11201507277YA/en unknown
- 2014-03-17 MX MX2015013092A patent/MX2015013092A/es unknown
- 2014-03-17 EP EP18167516.6A patent/EP3403666A1/en active Pending
- 2014-03-17 BR BR112015021266A patent/BR112015021266A2/pt not_active IP Right Cessation
- 2014-03-17 EP EP14765106.1A patent/EP2968449A4/en not_active Withdrawn
- 2014-03-17 CN CN201480015618.3A patent/CN105744946A/zh active Pending
- 2014-03-17 JP JP2016503333A patent/JP6670987B2/ja active Active
- 2014-03-17 RU RU2015144360A patent/RU2015144360A/ru unknown
-
2015
- 2015-09-09 IL IL241417A patent/IL241417A0/en unknown
-
2016
- 2016-07-17 US US15/212,277 patent/US10294285B2/en active Active
-
2019
- 2019-05-20 US US16/416,268 patent/US10676513B2/en active Active
- 2019-12-02 JP JP2019218277A patent/JP2020055833A/ja active Pending
-
2020
- 2020-06-09 US US16/896,213 patent/US20200325190A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014145368A2 (en) | 2014-09-18 |
| US10676513B2 (en) | 2020-06-09 |
| US20160362462A1 (en) | 2016-12-15 |
| EP3403666A1 (en) | 2018-11-21 |
| WO2014145368A3 (en) | 2014-11-27 |
| RU2015144360A (ru) | 2017-04-24 |
| IL241417A0 (en) | 2015-11-30 |
| AU2014233127A1 (en) | 2015-09-24 |
| KR20160030076A (ko) | 2016-03-16 |
| EP2968449A4 (en) | 2017-03-22 |
| CN105744946A (zh) | 2016-07-06 |
| CA2907439A1 (en) | 2014-09-18 |
| US20140275477A1 (en) | 2014-09-18 |
| EP2968449A2 (en) | 2016-01-20 |
| JP2020055833A (ja) | 2020-04-09 |
| US10294285B2 (en) | 2019-05-21 |
| US9394349B2 (en) | 2016-07-19 |
| SG11201507277YA (en) | 2015-10-29 |
| BR112015021266A2 (pt) | 2017-10-10 |
| JP2016515532A (ja) | 2016-05-30 |
| US20190337999A1 (en) | 2019-11-07 |
| JP6670987B2 (ja) | 2020-03-25 |
| US20200325190A1 (en) | 2020-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015013092A (es) | Modificación y nuevas composiciones de proteínas secretoglobinas de humano. | |
| CY1116728T1 (el) | Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων | |
| JOP20200055A1 (ar) | مركبات بيرازولو بيريميدينون واستخداماتها | |
| PH12017500402A1 (en) | Anti-glucagon antibodies and uses thereof | |
| MX2016016531A (es) | Metodos y composiciones para el tratamiento de las ulceras. | |
| GB2544270A8 (en) | Nucleic acids, peptides and methods | |
| EA201500261A1 (ru) | Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7 | |
| BR112015022934A8 (pt) | esteróides neuroativos, composições e usos destes | |
| EA201491470A1 (ru) | Композиции фактора viii и способы получения и использования подобных | |
| MX2011008094A (es) | Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos. | |
| MX374477B (es) | Composicion y productos que comprenden celulas senescentes para su uso en la regeneracion de tejidos | |
| MX336489B (es) | Hormona foliculo estimulante humana recombinante composicion farmaceutica que la comprende y uso de la misma. | |
| UY33280A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| TN2013000427A1 (en) | Modified acid alpha glucosidase with accelerated processing | |
| MX2011010908A (es) | Anticuerpos anti-tnf-alfa y sus usos. | |
| BR112013003823A2 (pt) | conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados | |
| WO2015067755A3 (en) | Novel methods and antibodies for treating coagulapathy | |
| MX379241B (es) | ANTICUERPOS DE UNIÓN A PROTOFIBRILLAS BETA AMILOIDE (Aß) MEJORADOS. | |
| NZ715203A (en) | Heparan sulphates | |
| WO2014140103A3 (en) | Thrombin sensitive coagulation factor x molecules | |
| MX2020010807A (es) | Peptidos promotores del crecimiento y usos de los mismos. | |
| BR112013009660A2 (pt) | proteína de fusão com fator de atividade ix | |
| MX2018002921A (es) | Composicion de hormona foliculo-estimulante mamifera con estabilidad incrementada. | |
| MX2021005843A (es) | Composiciones y métodos para aumentar la hemoglobina fetal y tratar la anemia de células falciformes. | |
| BR112015019568A2 (pt) | Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo |